

Manuscript version: Author's Accepted Manuscript

The version presented in WRAP is the author's accepted manuscript and may differ from the published version or Version of Record.

Persistent WRAP URL:

<http://wrap.warwick.ac.uk/118360>

How to cite:

Please refer to published version for the most recent bibliographic citation information. If a published version is known of, the repository item page linked to above, will contain details on accessing it.

Copyright and reuse:

The Warwick Research Archive Portal (WRAP) makes this work by researchers of the University of Warwick available open access under the following conditions.

© 2019 Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International <http://creativecommons.org/licenses/by-nc-nd/4.0/>.



Publisher's statement:

Please refer to the repository item page, publisher's statement section, for further information.

For more information, please contact the WRAP Team at: wrap@warwick.ac.uk.

1 **Evaluating the value of intrapartum fetal scalp blood sampling to predict adverse**
2 **neonatal outcomes: A UK multicentre observational study**

3 Bassel H.Al Wattar on Behalf of the AB-FAB study group¹

4 ¹ The UK trainee Audit and Research Collaborative in Obstetrics and Gynaecology: Aarti

5 Lakhiani, Adalina Sacco, Aditi Siddharth, Alexandra Bain, Alexandra Calvia, Atiyah Kamran,

6 Bing Tiong, Bethan Warwick, Caroline MacMahon, Diana Marcus, Emma Long, Gillian Coyle,

7 Gillian Elizabeth Lever, Gina Michel, Gomathy Gopal, Hana Baig, Hannah Louise Price, Hawra

8 Badri, Helen Stevenson, Helene Hoyte, Humaira Malik, Jade Edwards, Jennifer Hartley, Jennifer

9 Hemers, Jennifer Tamblyn, John Alexander William Dalton, Jonathan Frost, Kamana Subba,

10 Kathryn Baxter, Kavitha Sivakumar, Kelly Murphy, Konstantinos Papadakis, Laura Rachel

11 Bladon, Lorraine Kasaven, Louisa Manning, Mathew Prior, Mausumi Ghosh, Melanie Couch,

12 Melis Altunel, Melissa Pearce, Michael Cocker, Michael Stephanou, Michelle Jie, Minesh

13 Mistry, Mohammed Osama Wahby, Nabila Shahid Saidi, Nicola Louise Ramshaw, Nicola

14 Tempest, Nina Parker, Phoebe L Tan, Racheal Louise Johnson, Rachel Harris, Rachel Tildesley,

15 Ramya Ram, Ritu Painuly, Romana Cuffolo, Roberta Bugeja, Rose Ngadze, Rosie Grainger,

16 Sabitra Gurung, Sammy Mak, Sara Farrell, Sarah Cowey, Sarah Neary, Sarah Quinn, Simrit

17 Kaur Nijjar, Sophie Kenyon, Stephanie Lamb, Susan Tracey, Tara Lee, Therese Kinsella, Trecia

18 Davidson, Trent Corr, Uzo Sampson, Victoria McQueen, William Parry Smith, Zora

19 Castling

20

21 Corresponding author: Bassel H.Al Wattar – Warwick Medical School – The University of

22 Warwick - Coventry CV4 7AJ

23 Email: dr.basselwa@gmail.com

24

25 **Abstract:** (350)

26 **Objective:** To evaluate the value of fetal scalp blood sampling (FBS) as an adjunct test to
27 cardiotocography, to predict adverse neonatal outcomes.

28 **Study design:** A multicentre service evaluation observational study in forty-four maternity units
29 in the UK. We collected data retrospectively on pregnant women with singleton pregnancy who
30 received FBS in labour using a standardised data collection tool. The primary outcome was
31 prediction of neonatal acidaemia diagnosed as umbilical cord arterial pH<7.05, the secondary
32 outcomes were the prediction of Apgar scores<7 at 1st and 5th minutes and admission to the
33 neonatal intensive care unit (NICU). We evaluated the correlation between the last FBS blood
34 gas before birth and the umbilical cord blood and adjusted for time intervals. We constructed 2x2
35 tables to calculate the sensitivity, specificity, positive (PPV) and negative predictive value (NPV)
36 and generated receiver operating curves to report on the Area Under the Curve (AUC).

37 **Results:** In total, 1422 samples were included in the analysis; pH values showed no correlation
38 ($r=0.001$, $p=0.9$) in samples obtained within an hour ($n=314$), or within half an hour from birth
39 ($n=115$) ($r=-0.003$, $p=0.9$). A suboptimal FBS pH value (<7.25) had a poor sensitivity (22%) and
40 PPV (4.9%) to predict neonatal acidaemia with high specificity (87.3%) and NPV (97.4%).
41 Similar performance was noted to predict Apgar scores <7 at 1st (sensitivity 14.5%, specificity
42 87.5%, PPV 23.4%, NPV 79.6%) and 5th minute (sensitivity 20.3%, specificity 87.4%, PPV
43 7.6%, NPV 95.6%), and admission to NICU (sensitivity 20.3%, specificity 87.5%, PPV 13.3%,
44 NPV 92.1%). The AUC for FBS pH to predict neonatal acidaemia was 0.59 (95%CI 0.59-0.68,
45 $p=0.3$) with similar performance to predict Apgar scores <7 at 1st minute (AUC 0.55, 95%CI
46 0.51-0.59, $p=0.004$), 5th minute (AUC 0.55, 95%CI 0.48-0.62, $p=0.13$), and admission to NICU
47 (AUC 0.58, 95%CI 0.52-0.64, $p=0.002$)

48 Forty-one neonates had acidaemia (2.8%, 41/1422) at birth. There was no significant correlation
49 in pH values between the FBS and the umbilical cord blood in this subgroup adjusted for
50 sampling time intervals ($r= 0.03$, $p=0.83$).

51 **Conclusions:** As an adjunct tool to cardiotocography, FBS offered limited value to predict
52 neonatal acidaemia, low Apgar Scores and admission to NICU.

53 **Funding:** None

54 **Keywords:** Fetal scalp – Blood sampling – Intrapartum – Accuracy – Acidaemia – Asphyxia

55

56 **Introduction:**

57 Fetal surveillance in labour is an essential practice in modern obstetric to monitor fetal wellbeing
58 and reduce the risk of adverse neonatal outcomes. Cardiotocography (CTG) remains the primary
59 tool to monitor the fetal heart rate and screen for intrapartum hypoxia, however, due to its low
60 specificity, several adjunct diagnostic tools have been proposed to increase its accuracy.(1) Fetal
61 scalp blood sampling (FBS) is proposed as an objective test to assess the fetal metabolic status in
62 labour, measuring capillary pH and base excess values, thus prompting further interventions
63 when fetal acidaemia is suspected. Still, its effectiveness as an adjunct tool to CTG to improve
64 perinatal outcomes remains uncertain.(2)

65

66 In practice, many factors can affect the accuracy of FBS to predict fetal compromise such as
67 sample contamination, failure to obtain samples timely and underlying fetal complications like
68 anaemia and infection.(3) Such limitations call to question the value of using FBS as a gold
69 standard to evaluate the fetal metabolic status (4) especially within the diagnostic thresholds set
70 in current national guidelines.(2) We conducted a multi-centre observational service evaluation
71 study to assess the value of using FBS in labour to predict neonatal acidaemia and associated
72 adverse neonatal outcomes

73

74 **Methods:**

75 *Study design*

76 The study was conducted by members of The UK trainee Audit and Research Collaborative in
77 Obstetrics and Gynaecology (UKARCOG.org). The corresponding author is the study guarantor
78 and assumes responsibility for the completeness and accuracy of the data and analyses, and for
79 the fidelity of the study to the registered protocol.

80

81 The study protocol was conceived by the UKARCOG core group and approved by all
82 collaborators. We registered the protocol prospectively with the clinical governance department
83 at each of the participating maternity units. A copy of the protocol is publicly available on the
84 internet (www.UKARCOG.org). Our project was exempt from ethical approval as a service
85 evaluation study collecting data routinely recorded in the National Health Service (NHS).

86

87 *Participants*

88 We collected data retrospectively on pregnant women with a singleton pregnancy who
89 underwent FBS in labour and had umbilical cord blood gases recorded at birth. We identified
90 participants by screening the logs of blood gas analysers at participating units for paired FBS and
91 umbilical cord blood samples and then linked data to the women's electronic or paper-based
92 clinical notes. Samples with no paired pH values on both the FBS and the umbilical cord blood
93 gas were excluded. Samples with no paired arterial and venous umbilical cord blood gas were
94 also excluded from the analysis.

95

96 *Outcome measures*

97 The primary outcome was the accuracy to predict neonatal acidaemia defined as an arterial
98 umbilical cord pH value <7.05 .(2) The secondary outcomes were the accuracy to predict Apgar

99 scores < 7 at the 1st minute and the 5th minute, and admission to the neonatal intensive care unit
100 (NICU). We defined a FBS pH value as normal if it was > 7.25, suboptimal if it was 7.25-7.20
101 and abnormal if it was < 7.20. We defined a FBS lactate value as normal if it was < 4.2,
102 suboptimal if it was 4.2-4.8 and abnormal if it was > 4.8. (2)

103
104 We collected data on the: gestation age at delivery, gravidity, parity, duration of 1st and 2nd
105 stages of labour, incidence of maternal pyrexia (> 38.0 C°) in labour, incidence of meconium-
106 stained liquor in labour, birth weight, date and time of each FBS sample, cervical dilation at each
107 FBS sample, pH value, base excess value and lactate value on each FBS sample, date and time of
108 birth, birth outcome, mode of delivery, cord blood gas pH, base excess and lactate values, Apgar
109 scores at 1st and 5th minute of life, and admission to the NICU. Low birth weight was defined as
110 < 2500g.

111

112 *Data collection*

113 We collected data using a standardised paper-based data collection tool (Appendix 1). All
114 collaborators were debriefed on the use of the tool and confirmed its face validity. Collected
115 forms were coded, anonymised and entered into a standardised Excel-based database locally at
116 each participating unit. Anonymised data were merged centrally for the purpose of the analysis
117 as per the registered protocol.

118

119 *Statistical analysis*

120 We used the results of the last FBS before birth and the umbilical cord blood gas test values
121 to construct 2x2 tables and calculate the sensitivity, specificity, positive predictive value

122 (PPV) and negative predictive value (NPV) for each of the following test thresholds to
123 predict the primary and secondary outcomes: suboptimal pH, abnormal pH, suboptimal
124 lactate and abnormal lactate. We generated receiver operating characteristic curves for
125 these test thresholds and reported on the Area Under the Curve (AUC) with 95%
126 confidence intervals (CI) to predict adverse neonatal outcomes with lower test values
127 indicating a more positive test. We used Pearson and partial correlation tests to evaluate
128 the correlation between the pH values on the FBS and the umbilical cord blood samples
129 adjusted for sampling time intervals . We performed a multivariate logistic regression
130 modelling to determine factors affecting the accuracy of FBS and reported using relative
131 risk (RR) and 95%CI on the association between each FBS pH threshold and relevant
132 maternal and neonatal adverse outcomes. All statistical analyses were performed in SPSS
133 v20 (IBM Corp. Armonk, NY).

134

135 **Results**

136 *General findings*

137 We collected data on 1670 women who received a FBS in labour, sample dates ranged between
138 January 2016 and May 2018. We excluded 248 records due to incomplete data, and included
139 1422 in the analysis. FBS was performed twice in 373 women, three times in 59, and four times
140 in 17 women.

141 The median gestation age was 40+3 (range 34+2 - 42+1), and the median birth weight was 3405
142 (range 1940 - 5050). Labour was induced in two-thirds of women (59.6%, 844/1422) and 20%
143 had a normal vaginal delivery (20.4%, 297/1421). Almost half of the included women were
144 delivered via emergency caesarean section (43.1%, 613/1421) and 36% had a vaginal

145 instrumental delivery (35.6%, 507/1421). The incidence of maternal pyrexia in labour was 10.7%
146 (153/1422) and meconium stained liquor was diagnosed in 18.9% (269/1422). Only 10.4% of
147 neonates had a low birth weight <2500g (10.4%, 148/1422). (Table 1)

148
149 A total of 296 fetuses had an Apgar scores <7 at 1st minute (296/1422, 20.8%) and 69 had a
150 scores <7 at the 5th minute (69/1422, 4.8%). Only 8% needed admission to NICU (118/1422,
151 8.2%). A quarter of fetuses had a suboptimal pH (<7.25) on the last FBS test before birth
152 (12.9%, 184/1422) and 77 had an abnormal pH (<7.20) (5.4%, 77/1422). Lactate was only
153 available in 187 FBS tests and was suboptimal (>4.2) in 31 fetuses (16.5%, 31/187) and
154 abnormal in 23 (12.2%, 23/187).

155 Overall there was poor correlation between FBS blood markers and those on the umbilical cord
156 (pH $r=0.22$, $p=0.001$; BE $r=0.36$ $p=0.001$; Lactate $r=0.23$, $p=0.002$). We evaluated the
157 correlation between the pH values of the FBS and the umbilical cord arterial blood gas in
158 samples performed within an hour from birth and adjusted for sampling time intervals. There
159 was no significant correlation ($r=0.001$, $p=0.9$) in pH values in samples obtained within an hour
160 ($n=314$) from birth, or in those within half an hour from birth ($n=115$) ($r=-0.003$, $p=0.9$).

161 A suboptimal FBS pH value (<7.25) had a poor sensitivity (22%) and PPV (4.9%) to predict
162 neonatal acidaemia with high specificity (87.3%) and NPV (97.4%). Similar performance was
163 noted to predict Apgar scores <7 at 1st (sensitivity 14.5%, specificity 87.5%, PPV 23.4%, NPV
164 79.6%) and 5th minute (sensitivity 20.3%, specificity 87.4%, PPV 7.6%, NPV 95.6%), and
165 admission to NICU (sensitivity 20.3%, specificity 87.5%, PPV 13.3%, NPV 92.1%) (Table 2).
166 Similarly, an abnormal FBS pH (<7.20) had low sensitivity (7.3%) and PPV (3.9%) and high

167 specificity (94.6%) and NPV (97.2%) for neonatal acidaemia with similar performance to predict
168 the remaining adverse neonatal outcomes (Table 2).

169

170 Our ROC analysis revealed a modest performance for FBS pH to predict neonatal acidaemia
171 with an AUC of 0.59 (95%CI 0.59-0.68, p=0.3) (Figure 1) and similar performance for
172 predicting Apgar scores <7 at 1st minute (AUC 0.55, 95%CI 0.51-0.59, p=0.004), 5th minute
173 (AUC 0.55, 95%CI 0.48-0.62, p=0.13), and admission to NICU (AUC 0.58, 95%CI 0.52-0.64,
174 p=0.002). (Table 2) (Appendix 3)

175

176 Neonatal acidaemia was diagnosed in 41 neonates (2.8%, 41/1422). Over half of those neonates
177 had an Apgar score <7 at the 1st minute (63.4%, 26/41), 6 had a score <7 at the 5th minute
178 (14.6%, 6/41), and 7 required admission to NICU (17%, 7/41) (Table 1). Twenty were delivered
179 via an emergency caesarean section (20/41, 48.7%) and 13 via an instrumental vaginal delivery
180 (13/41,31.7%). FBS was conducted in the second stage of labour in 10 of these foetuses (10/41,
181 24.3%). There was no significant correlation in pH values between the FBS and the umbilical
182 cord samples in this subgroup adjusted for sampling time intervals (range 15-462 minutes) (r=
183 0.03, p=0.83), similar findings were found for BE (r=0.29, p=0.08). Paired Lactate samples were
184 available in only five cases in this subgroup.

185

186 Due to the small sample size of paired pH and lactate (n=187), we were unable to accurately
187 evaluate the performance of suboptimal and abnormal FBS lactate to predict the primary and

188 secondary outcomes. Overall lactate showed a similar performance to pH with high specificity
189 and NPV and low sensitivity and PPV for all adverse neonatal outcomes (Appendix 2).

190

191 *Associated factors*

192 Women with a suboptimal FBS pH had a RR of 1.62 (95%CI 1.42-1.83) to receive an emergency
193 caesarean section. A similar risk was reported for those with an abnormal FBS pH (RR 1.82,
194 95%CI 1.58-2.10). Repeating the FBS three or more times in labour was associated with a RR of
195 1.22 for receiving an emergency caesarean section (95%CI 0.95-1.57). There was no significant
196 association between the FBS pH value and the diagnosis of maternal pyrexia (BE -.246, p=0.37),
197 the diagnosis of meconium stained liquor in labour (BE -.119, p=0.55) or the mode of delivery
198 (vaginal vs emergency caesarean section BE 0.298, p=0.058). There was a negative association
199 with low birth weight (BE -.461, p=0.045).

200

201 **Discussion**

202 *Summary of findings*

203 Our study suggests an overall limited value for using FBS as an adjunct test to CTG to predict
204 adverse outcomes in fetuses at risk of intrapartum asphyxia. FBS pH demonstrated high
205 specificity and negative predictive value to predict neonatal acidaemia, thus, it is a good test to
206 rule out uncompromised fetuses with an abnormal CTG test, but not to rule in those at risk.

207 Women who had a suboptimal or abnormal FBS pH value had a higher risk of receiving an
208 emergency caesarean section, however, we were not able to record the indication for delivery in

209 all cases. Interestingly, only a small number of babies delivered via an emergency caesarean
210 section were found to have marked neonatal acidaemia (20/659, 1.4%). This comes in line with
211 evidence suggesting that using FBS did not reduce the rate of emergency caesarean section as
212 hoped.(5) FBS pH values did not correlate with those on the umbilical cord within an hour of
213 delivery or in those neonates with acidaemia at birth, suggesting a limited value of using FBS to
214 aid decision making in labour with a modest AUC for predicting all adverse neonatal outcomes
215 ranging from 0.55 to 0.59.

216

217 *Strength and limitations*

218 We collected data from 44 maternity units which provide a pragmatic national perspective on the
219 current use of FBS in the NHS. We registered our protocol prospectively at each participating
220 maternity unit and used a standardised data collection tool to reduce performance bias. We
221 obtained a large and diverse sample, though interestingly many women were induced (60%) and
222 only a fifth had a normal vaginal delivery (20%). This could support an association between
223 using FBS and increased risk in labour leading to higher rate of interventions.

224 Our findings are not without limitations, we collected data retrospectively across multiple sites to
225 obtain a large sample and improve the study power, , however, we could not obtain consecutive
226 cases across all sites The practice of FBS is standardised across the NHS and reported outcomes
227 are collected routinely in standardised maternity records as per established national guidelines.

228 We, therefore, do not perceive significant variation in data collection. We did not record the
229 indication for performing the FBS and presumed it to follow an abnormal intrapartum CTG.

230 Variations in CTG interpretations, prompting FBS testing, are likely and our findings should be

231 interpreted pragmatically. Our study design is subject to the treatment paradox, interventions to
232 prompt early delivery and neonatal resuscitation at birth are likely to mend the metabolic status
233 of compromised neonates, thus improving their umbilical cord pH values. Performing in utero
234 resuscitation such as change in maternal position and use of tocolytics could also change the fetal
235 metabolic status from time of FBS to time of birth. We planned to adjust correlation testing for
236 sampling time intervals between the last FBS and time of birth. However, our data suffered from
237 high loss of times recorded and we could only adjust in samples within an hour of birth.

238 We aimed to collect data from all maternity units in the UK, but several units withdraw due to
239 low numbers of FBS tests performed per year. We collected a limited number of samples where
240 FBS lactate was recorded which reduced our ability to accurately evaluate its predictive value.

241

242 *Implication for clinical practice*

243 The primary aim of using FBS is to improve the detection of intrapartum hypoxia and reduce
244 unnecessary interventions when a CTG is judged to be abnormal. Due to its limited specificity,
245 using CTG as the sole fetal surveillance tool could increase the rate of unnecessary caesarean
246 sections and the associated adverse neonatal and maternal outcomes.(5) Our findings support the
247 ability of a normal FBS pH to reassure health professionals and mothers on the safety of a fetus
248 with an abnormal CTG. However, a suboptimal or abnormal pH using current thresholds seems
249 of limited value to guide further action. This echoes the findings of similar studies confirming
250 the limited value of FBS pH to aid decision making in intrapartum care.(6) Adopting a more
251 comprehensive evaluation of the fetal metabolic status using BE and Lactate in addition to pH
252 could offer better guidance to clinicians.(7)

253 The current national guideline in the UK recommends performing a FBS when a CTG is judged
254 to be ‘pathological’.(2) However, with many diagnostic criteria used to classify and interpret
255 CTG in labour, the poor inter/intra-rater reliability could lead to excessive use of FBS. Some
256 CTG features are considered more abnormal than others (2,8,9), evaluating the correlation
257 between certain CTG features and the findings on the FBS capillary pH could offer better
258 guidance on if and when FBS is warranted. Developing a deeper understanding of the fetal
259 pathophysiology and the fetal response to intrapartum hypoxic stress may obviate the need for
260 FBS.(10)

261

262 Current guidance supports the validity of FBS predictive value for an hour in the first stage of
263 labour and half an hour in the second stage.(2) However, there is limited evidence on the
264 longitudinal changes in pH values in labour. This was evident in our sample with no apparent
265 correlation in pH values within an hour from birth. Khuehle et al presented better correlation in
266 pH value within an hour from birth (6), though their findings did not adjust for sampling time
267 intervals. Clearly, the depreciation rate in the fetal pH during intrapartum hypoxic stress depends
268 on the individual reserve of the fetus, the rapidity and the intensity of intrapartum hypoxia.
269 Therefore, from a pathophysiological point of view, having ‘arbitrary’ cut offs (60 minutes or 30
270 minutes) to obtain new samples appears illogical. A threshold for the maximum number of
271 repeated FBS samples in labour remains unknown. Recent evidence suggested that repetitive
272 fetal blood sampling may double the caesarean section rate (11) which is consistent in our
273 findings with a RR of 1.62 .

274 The use of capillary lactate seems to offer an easier and more versatile test with reduced failure
275 rate to obtain a sample.(12) Our sample was not sufficient to evaluate its performance as a

276 predictive test and more research is needed to evaluate its role in modern obstetrics. Several
277 studies reported better correlation in Lactate values between FBS and cord samples (13,14), still
278 no evidence in improving neonatal or maternal outcomes was noted in two randomised trials.
279 (15)

280

281 *Future research*

282 To date, many adjunct tests to CTG have been proposed to aid the diagnosis of intrapartum
283 hypoxia.(12) While several meta-analyses evaluated their efficacy,(12) there is limited evidence
284 on their accuracy as predictive tools in everyday practice.

285 The current technology employed to obtain fetal capillary blood is largely undeveloped since its
286 introduction in 1960.(10) Improving the sample acquisition process might increase the FBS
287 accuracy and effectiveness by reducing sample collection failure and contamination.(4) The use
288 of FBS pH should be critically reviewed in the light of our findings, and recent evidence
289 advocating the value of fetal scalp stimulation to provide better information with on fetal
290 wellbeing.(16) Fetal surveillance is a complex intervention with many confounding factors such
291 as the availability of trained staff and the complexity of associated maternal co-morbidity in
292 labour. Evaluating the efficacy of fetal surveillance tools in randomised trials offers a snapshot
293 evaluation of a standardised practice during the lifetime of the trial.(17) Thus, larger
294 effectiveness and longitudinal multicentre follow-ups studies are needed to draw more accurate
295 conclusions and contrast the benefit of using these tools to improve short and long-term neonatal
296 and maternal outcomes.

297

298 **Conclusion:** As an adjunct tool to cardiotocography, FBS offered limited value to predict
299 neonatal acidaemia, low Apgar Scores and admission to NICU.

300

301 **Acknowledgement:**

302 - The authors appreciate with great gratitude the input of Mr Edwin Chandraharan -

303 Consultant Obstetrician and Gynaecologist at St. George's NHS Trust- who critically

304 reviewed and improved our manuscript.

305 - The trainees of the UKARCOG network appreciate the help and guidance received from

306 consultants on the RCOG academic board and participating NHS maternity units to

307 accomplish this study.

308 **Funding:** None

309 **Disclosure of interest:** All authors have nothing to declare

310 **Contribution to authorship:**

311 Bassel H.Al Wattar conceived the idea, wrote the first protocol and manuscript, analysed the data

312 and acted as the study chief investigator. William Parry smith, Nicola Tempest, Mathew Prior,

313 Jennifer Tamblyn, Jonathan Frost and Emma Long revised the protocol and acted as the study

314 management committee. All remaining co-authors actively collected data, oversaw the study

315 conduct and contributed critically to the final manuscript.

316 **References:**

- 317 1. Devoe LD. Future perspectives in intrapartum fetal surveillance. *Best Pract Res Clin*
318 *Obstet Gynaecol.* 2016;30:98–106.
- 319 2. The National Institute for Health and Care Excellence. Intrapartum care for healthy
320 women and babies. 2014; Available from: <https://www.nice.org.uk/guidance/cg190>
- 321 3. Jacobson L, Rooth G. Interpretative aspects on the acid- base composition and its
322 variation in fetal scalp blood and maternal blood during labour. *BJOG An Int J Obstet*
323 *Gynaecol.* 1971;78(11):971–80.
- 324 4. Mahendru AA, Lees CC. Is intrapartum fetal blood sampling a gold standard diagnostic
325 tool for fetal distress? *Eur J Obstet Gynecol Reprod Biol.* 2011;156(2):137–9.
- 326 5. Alfirevic Z, Devane D, Gyte GM. Continuous cardiotocography (CTG) as a form of
327 electronic fetal monitoring (EFM) for fetal assessment during labour. *Cochrane Database*
328 *Syst Rev.* 2006;3(3):81.
- 329 6. Kuehnle E, Herms S, Kohls F, Kundu S, Hillemanns P, Staboulidou I. Correlation of fetal
330 scalp blood sampling pH with neonatal outcome umbilical artery pH value. *Arch Gynecol*
331 *Obstet.* 2016;294(4):763–70.
- 332 7. Heinis AMF, Spaanderman ME, Gunnewiek JMTK, Lotgering FK. Scalp blood lactate for
333 intra- partum assessment of fetal metabolic acidosis. *Acta Obstet Gynecol Scand.*
334 2011;90(10):1107–14.
- 335 8. Ayres- de- Campos D, Spong CY, Chandrharan E. FIGO consensus guidelines on
336 intrapartum fetal monitoring: Cardiotocography. *Int J Gynecol Obstet.* 2015;131(1):13–

- 337 24.
- 338 9. Kouskouti C, Jonas H, Regner K, Ruisinger P, Knabl J, Kainer F. Validation of a new
339 algorithm for the short-term variation of the fetal heart rate: an antepartum prospective
340 study. *J Perinat Med*. 2018;46(6):599–604.
- 341 10. Chandraharan E. Fetal scalp blood sampling during labour: is it a useful diagnostic test or
342 a historical test that no longer has a place in modern clinical obstetrics? *BJOG An Int J*
343 *Obstet Gynaecol*. 2014;121(9):1056–62.
- 344 11. Holzmann M, Wretler S, Cnattingius S, Nordström L. Neonatal outcome and delivery
345 mode in labors with repetitive fetal scalp blood sampling. *Eur J Obstet Gynecol Reprod*
346 *Biol*. 2015;184:97–102.
- 347 12. Wiberg-Itzel E, Lipponer C, Norman M, Herbst A, Prebensen D, Hansson A, et al.
348 Determination of pH or lactate in fetal scalp blood in management of intrapartum fetal
349 distress: randomised controlled multicentre trial. *Bmj*. 2008;336(7656):1284–7.
- 350 13. Kruger K, Hallberg B, Blennow M, Kublickas M, Westgren M. Predictive value of fetal
351 scalp blood lactate concentration and pH as markers of neurologic disability. *Am J Obstet*
352 *Gynecol*. 1999;181(5):1072–8.
- 353 14. Kastendieck E, Paulick R, Martius J. Lactate in fetal tissue during hypoxia; correlation to
354 lactate, pH and base deficit in the fetal blood. *Eur J Obstet Gynecol Reprod Biol*.
355 1988;29(1):61–71.
- 356 15. East CE, Leader LR, Sheehan P, Henshall NE, Colditz PB, Lau R. Intrapartum fetal scalp
357 lactate sampling for fetal assessment in the presence of a non- reassuring fetal heart rate

- 358 trace. Cochrane Database Syst Rev. 2015;(5).
- 359 16. Tahir Mahmood U, O’Gorman C, Marchocki Z, O’Brien Y, Murphy DJ. Fetal scalp
360 stimulation (FSS) versus fetal blood sampling (FBS) for women with abnormal fetal heart
361 rate monitoring in labor: a prospective cohort study. J Matern Neonatal Med.
362 2018;31(13):1742–7.
- 363 17. Ayres-de-Campos D. Introduction: why is intrapartum foetal monitoring necessary–
364 impact on outcomes and interventions. Best Pract Res Clin Obstet Gynaecol. 2016;30:3–8.
- 365
- 366